OC-07: ANTI-HYPERNOCICEPTIVE EFFECT OF MANGIFERIN IN PERSISTENT AND NEUROPATHIC PAIN MODELS IN RATS

J Pharm Pharmacogn Res 3(suppl. 1): S17, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Oral Communication

OC-07: ANTI-HYPERNOCICEPTIVE EFFECT OF MANGIFERIN IN PERSISTENT AND NEUROPATHIC PAIN MODELS IN RATS

Garrido B1, Garrido G2, Castro M1, Merino N1, Valdés O1, Rodeiro I3, Hernández I3, Godoy J4, Ferreira S4, Delgado R1.

1Laboratorio de Farmacología y Toxicología, Centro de Investigación y Desarrollo de Medicamentos, Ave. 26 No. 1605, Nuevo Vedado, La Habana 10600, Cuba. E-mail: beatriz.garrido@infomed.sld.cu
2Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Edificio Ñ3, Universidad Católica del Norte, Angamos 0610, Antofagasta 1270709, Chile.
3Centro de Bioproductos Marinos, Loma y 37, Nuevo Vedado, La Habana 10300, Cuba.
4Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Av. Bandeirantes, 3900, 14049-900 Ribeirão Preto, SP, Brazil.

 

Introduction: Several evidences suggest the potentiality of the glucosylxanthone mangiferin (MG) to modulate some of the molecular targets implicated in neuropathic pain mechanisms, especially central sensitization, through of its long term effects mediated by transcriptional changes. Nevertheless, a transient mechanism of MG on nociceptive pathway could be implicated. Previously, we advised that MG could be used to treat neuropathic pain supported in preclinical data and preliminary clinical reports with Mangifera indica L. extract formulations that contain 15–20% of this polyphenol. Material and Methods: The present study examines its possible effect on pain-related behaviors in a tonic acute pain model (formalin test at 5%) and in a chronic constriction injury (CCI) model to clarify the underlying transient and long-term mechanisms. Results: Acute administration of MG (10–100 mg/kg, i.p.) reduced licking/biting exclusivity in the tonic phase of formalin test in a naloxone and yohimbine-sensitive manner. This effect was enhanced by a nonselective nitric oxide synthase (NOS) inhibitor (NG-monomethyl-L-arginine) and by a non-competitive N-methyl-D-aspartate (NMDA) antagonist (ketamine), but it was reversed by the NOS substrate (L-arginine). Pre-treatment with intrathecal yohimbine prevented the anti-hypernociceptive effect of systemic MG. Pre-treatment during 4 days before surgical and 3 days after CCI with MG (50 mg/kg, i.p.) reduced mechanical hypernociception and decreased the signs of Wallerian degeneration (WD) of the sciatic nerve. MG improved the PC-12 cellular viability exposure to glutamate-mediated neuronal death, also involved in neuropathic pain. Conclusions: The findings of this study suggest that MG shows ability to decrease tonic pain in the formalin test. A transient activity of this xanthone on nociceptive pathways mediated by α2 adrenergic receptors in cooperation with the opioid system could be involved, at least in part, in this effect. Its neuroprotective effect by preventing WD in mononeuropathic rats could be implicated in the mechano-antihypernociceptive long-term mechanisms. Financial Support: Projects MINSAP № 0808001 (Cuba), CAPES № 120/2011 (Brazil), and FONDECYT № 1130601 (Chile).

Citation Format: Garrido B, Garrido G, Castro M, Merino N, Valdés O, Rodeiro I, Hernández I, Godoy J, Ferreira S, Delgado R (2015) Anti-hypernociceptive effect of mangiferin in persistent and neuropathic pain models in rats. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S17. Abstract nr OC-07.